Johnson & Johnson Development Corporation and MP Healthcare Venture Management join drugs peer GlaxoSmithkline in backing Genocea Biosciences.
Two other corporate venturing units have joined drugs company GlaxoSmithkline’s (GSK) SR One unit in the $35m series B round for Genocea Biosciences, a US-based vaccine development company.
Johnson & Johnson Development Corporation, which invests on behalf of medical device company Johnson & Johnson, and MP Healthcare Venture Management, a jointly owned subsidiary of Mitsubishi Tanabe Pharma and its parent company, Mitsubishi Chemical, were Genocea’s two new investors.
Alongside venture capital firm Skyline Ventures as the third new investor,…
